iCAD Corp - ICAD Company Value to Revenue Ratio

iCAD, Inc. (ICAD) develops intelligent systems for the early diagnosis of breast cancer tailored for clinics and radiology centers. The company's price-to-sales ratio clearly demonstrates market expectations, with the current value of the indicator standing at . The business generates revenue through the sale of mammogram analysis software, while its growth strategy relies on organic SaaS development and the integration of algorithms into equipment from tomograph manufacturers.
iCAD - analytical breakdowns and key metrics (ICAD)

The EV/Sales metric determines the enterprise value of a business, including debt and excluding cash, relative to annual revenue, allowing investors to assess the premium paid per unit of revenue against market norms. The EV/Sales trend reflects the capitalization of iCAD, Inc. (ICAD) innovations in AI cancer diagnostics, where the efficiency of cloud architecture and ESG standards determine valuation sustainability and the risk of a price correction.